Compare Exelon Corporation Common Stock (EXC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelon Corporation Common Stock vs Neurocrine Biosciences Inc — how do they compare? Exelon Corporation Common Stock trades at $41.74 (market cap $42.75B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Exelon Corporation Common Stock is far larger — about 2.9× Neurocrine Biosciences Inc's market cap, and Exelon Corporation Common Stock pays a 4.05% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| EXC | NBIX | |
|---|---|---|
Market Cap | $42.75B | $14.60B |
Volume | 7,084,069 | 1,075,694 |
Sector | Utilities | Health |
52-Week High | $50.29 | $185.50 |
52-Week Low | $40.20 | $123.10 |
Enterprise Value | $93.61B | $14.61B |
Dividend Yield | 4.05% | — |
Typical Hold Time | — | 23 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Exelon Corporation Common Stock
Exelon is the parent company of six regulated electric and natural gas utilities. Its utilities include Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO, and Pepco.
Read more on EXC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
